COVID-19
FAQ for Outpatient
Frequently Asked Questions for Outpatient
According to the most recent guidelines, the CDC now recommends that wearing cloth face coverings in public settings where other social distancing measures are difficult to maintain (e.g., grocery stores and pharmacies), especially in areas of significant community-based transmission.
The following are printables can be used for education purposes.

Courtesy of Corri Levine

Courtesy of WHO

Homemade Mask Instructions, more examples are found on CDC's website
Last Updated 9 months ago
Please refer patients/community members to the following resources:
Last Updated 9 months ago
ACE Inhibitors/ARBs:
- No clinical evidence that these agents may help or worsen COVID-19 .
- ACE inhibitors/ARBs should not be discontinued in COVID-19 patients.
- Only consider discontinuation if acute kidney injury, hypotension or other contraindications develop.
NSAIDs:
- FDA, WHO and EMA stated that NO clinical data at this point suggests increased risk in patients with COVID-19 using NSAIDs.
- Acetaminophen is preferred for fever in COVID-19 (except normal contraindication eg poor liver function).
Corticosteroids:
- Current evidence does not support early CS use in mild-moderate disease without comorbidities.
- Higher mortality, longer length of stay, and higher rate of bacterial infection.
Sources:
EMA gives advice on the use of NSAID for COVID-19. 2020Mar18. Available from: https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19
FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. 2020Mar19. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19
JHMI Clinical Guidance for Available Pharmacologic Therapies for COVID-19. 2020Apr7. Available from: https://www.hopkinsguides.com/hopkins/ub?cmd=repview&type=479-1130&name=5_538747_PDF
Lee N, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. 2004Dec31. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15494274
MGH COVID-19 Treatment Guidance. 2020Apr14. Available from: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/mass-general-COVID-19-treatment-guidance.pdf
Stockman L, et al. SARS: systematic review of treatment effects. 2006Sep3. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16968120
Wax R, et al. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. 2020Feb7. Available from: https://link.springer.com/content/pdf/10.1007/s12630-020-01591-x.pdf
Wu C, et al. Risk Factors Associated With ARDS and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. 2020Mar13. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32167524
Zhenwei Y, et al. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. 2020Mar31. Available from: https://www.journalofinfection.com/article/S0163-4453(20)30191-2/pdf
Last Updated 8 months ago
Missing content? Submit a content suggestion
According to the most recent guidelines, the CDC now recommends that wearing cloth face coverings in public settings where other social distancing measures are difficult to maintain (e.g., grocery stores and pharmacies), especially in areas of significant community-based transmission.
The following are printables can be used for education purposes.



Please refer patients/community members to the following resources:
Last Updated 9 months agoACE Inhibitors/ARBs:
- No clinical evidence that these agents may help or worsen COVID-19 .
- ACE inhibitors/ARBs should not be discontinued in COVID-19 patients.
- Only consider discontinuation if acute kidney injury, hypotension or other contraindications develop.
NSAIDs:
- FDA, WHO and EMA stated that NO clinical data at this point suggests increased risk in patients with COVID-19 using NSAIDs.
- Acetaminophen is preferred for fever in COVID-19 (except normal contraindication eg poor liver function).
Corticosteroids:
- Current evidence does not support early CS use in mild-moderate disease without comorbidities.
- Higher mortality, longer length of stay, and higher rate of bacterial infection.
Sources:
EMA gives advice on the use of NSAID for COVID-19. 2020Mar18. Available from: https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19
FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. 2020Mar19. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19
JHMI Clinical Guidance for Available Pharmacologic Therapies for COVID-19. 2020Apr7. Available from: https://www.hopkinsguides.com/hopkins/ub?cmd=repview&type=479-1130&name=5_538747_PDF
Lee N, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. 2004Dec31. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15494274
MGH COVID-19 Treatment Guidance. 2020Apr14. Available from: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/mass-general-COVID-19-treatment-guidance.pdf
Stockman L, et al. SARS: systematic review of treatment effects. 2006Sep3. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16968120
Wax R, et al. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. 2020Feb7. Available from: https://link.springer.com/content/pdf/10.1007/s12630-020-01591-x.pdf
Wu C, et al. Risk Factors Associated With ARDS and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. 2020Mar13. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32167524
Zhenwei Y, et al. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. 2020Mar31. Available from: https://www.journalofinfection.com/article/S0163-4453(20)30191-2/pdf
Last Updated 8 months ago